NCT04747964View on ClinicalTrials.gov

A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

April 19, 2021

Study Completion Date

April 19, 2021

Conditions
Hemophilia
Interventions
DRUG

STSP-0601 for Injection

Subjects will receive one single lowest dose of STSP-0601 for Injection following protocol requirements

DRUG

STSP-0601 for Injection

Subjects will receive one single low dose of STSP-0601 for Injection following protocol requirements

DRUG

STSP-0601 for Injection

Subjects will receive one single low-intermediate dose of STSP-0601 for Injection following protocol requirements

DRUG

STSP-0601 for Injection

Subjects will receive one single intermediate dose of STSP-0601 for Injection following protocol requirements

DRUG

STSP-0601 for Injection

Subjects will receive one single high dose of STSP-0601 for Injection following protocol requirements

DRUG

STSP-0601 for Injection

Subjects will receive one single highest dose of STSP-0601 for Injection following protocol requirements

Trial Locations (1)

Unknown

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY

NCT04747964 - A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor | Biotech Hunter | Biotech Hunter